Dsicover a recent study that compared Stockholm3 with other established biomarkers for prostate cancer screening. Learn more.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

A biomarker, PROSTOX, predicted late genitourinary toxicity accurately in patients with prostate cancer, yielding an area under the curve of 0.76.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.

According to Research by SNS Insider, Global Prostate Cancer Diagnostics Market Growth is Fueled by Growing Demand for Advanced Biomarker Testing, AI Diagnostics, and Outpatient Screening Services ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recen ...

in patients with prostate cancer HealthDay News — A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® ...

(HealthDay News) — A biomarker consisting primarily of microRNA ... toxicity in patients with prostate cancer, according to a study published online April 7 in Clinical Cancer Research.

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...